SCM
IONS icon

Segantii Capital Management’s Ionis Pharmaceuticals IONS Stock Holding History

Segantii Capital Management’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-300
Closed -$12K – 159
2017
Q1 		$12K Buy
+300
New +$13.5K ﹤0.01% 367

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Segantii Capital Management's IONS Position: Q2 2017 in Review

Segantii Capital Management sold out of Ionis Pharmaceuticals (IONS) in Q2 2017, closing a stake of 300 shares — an estimated $12K sold.

Segantii Capital Management first reported a position in IONS in Q1 2017 and held it in 1 quarter. The position peaked at $12K in Q1 2017. 293 funds tracked by Wall St. Rank hold IONS as of Q2 2017.

  • Segantii Capital Management reported no remaining Ionis Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Segantii Capital Management sold 300 Ionis Pharmaceuticals shares in Q2 2017, an estimated $12K.
  • Segantii Capital Management first reported a position in Ionis Pharmaceuticals in Q1 2017 and held it in 1 quarter.
  • Segantii Capital Management's Ionis Pharmaceuticals position peaked at $12K in Q1 2017.
  • 293 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2017.

Based on Segantii Capital Management's 13F filing for Q2 2017, filed 2 Aug 2017.